Multi-agent chemotherapy for refractory head and neck cancer
The MEMOCLUB regimen is a feasible salvage therapy in refractory HNSCC, which demonstrates reasonable efficacy and tolerability. The addition of cetuximab significantly prolonged survival in cetuximab-naive patients, suggesting that its coadministration is an advantageous strategy for this specific subgroup of platinum-refractory R/M HNSCC patients.
Authors
- T. H. Chen
- S K Tai
- P M-S Chang
- M-H. Yang
- J. K. Lin
- I-Wei Ho
- Pen-Yuan Chu
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- E-Da Hospital (TW)
- Changhua Christian Hospital (TW)
- I-Shou University (TW)
Publication Details
- Journal
- Journal of the Chinese Medical Association
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1097/jcma.0000000000001340
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00